Ellen Matloff, C.G.C., Director, Yale Cancer Genetic CounselingBio and Contact Info
Listen (5:05) Genetic counseling before the book was written
Listen (6:10) Myriad actions unprecedented
Listen (4:32) 30-40 % of all genetic tests ordered in error
Listen (5:12) Patents needed for business incentive?
Listen (3:09) Too few genetic counselors? Just Myriad propaganda
Listen (4:02) What is the Myriad database?
Listen (5:26) Why is the gene patent decision so personal for you?
Listen (2:32) DTC genomics not accurate, protected or helpful
When Ellen Matloff heard news of the recent Supreme Court decision invalidating some of Myriad's BRCA patents, she was overcome with tears. Tears of relief.
The first genetic counselor at Yale's School of Medicine, Ellen has had a front row seat to the long saga of gene patents, particularly the BRCA patents of Myriad Genetics. In today's interview Ellen recalls the days when the BRCA genes were first made known and explains the huge benefits the gene tests provided to her patients.
Then Myriad cracked down on their patents in a way Ellen calls "unprecedented" and "surreal."
Getting snubbed at every turn by Myriad--and then by her own peers for taking a position against gene patents has made this journey very personal for Ellen. Today she tells her view of gene patent history and gives her take on the burgeoning world of clinical genomics.
Podcast brought to you by: Chempetitive Group - "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."